FDA Expands Sunscreen Options for the First Time in 20 Years

FDA Adds Bemotrizinol as New Sunscreen Active Ingredient

The U.S. Food and Drug Administration (FDA) has expanded sunscreen options by adding bemotrizinol to the list of permitted active ingredients for over-the-counter (OTC) sunscreens. This marks the first new active ingredient added to the OTC sunscreen monograph since the late 1990s. The action, finalized within seven months of its proposed order, aligns with the Make America Healthy Again (MAHA) Strategy Report. Bemotrizinol, which has been safely used in Europe for decades, provides protection against both ultraviolet A and B rays with low skin absorption. The FDA considers it Generally Recognized As Safe and Effective (GRASE) for use by adults and children 6 months of age and older. The addition was initiated by an OTC monograph order request from DSM Nutritional Products LLC, utilizing a streamlined process established by the CARES Act.

• Historic Regulatory Milestone: The FDA's decision to add bemotrizinol to the OTC sunscreen monograph is a significant event, being the first new active ingredient approved for sunscreens in the U.S. since the late 1990s. This move is a direct outcome of the Trump Administration’s MAHA Strategy Report, aimed at advancing innovation and increasing competition in the sunscreen market, bringing the U.S. in line with global standards where bemotrizinol has been safely used for decades.
• Safety and Efficacy Profile: Bemotrizinol offers broad-spectrum protection against both ultraviolet A and B rays, crucial for comprehensive sun protection. Importantly, it demonstrates low levels of absorption through the skin into the body, contributing to its favorable safety profile. The FDA has officially deemed bemotrizinol as Generally Recognized As Safe and Effective (GRASE) for use in sunscreens for individuals aged 6 months and older, ensuring consumer confidence in its application.
• Streamlined Regulatory Process: This approval highlights the effectiveness of modernized regulatory processes, specifically the streamlined approach established by the CARES Act for OTC monograph drugs. The FDA finalized the administrative order within seven months of issuing the proposed order, demonstrating an efficient pathway for bringing innovative products to market. This process, initiated by DSM Nutritional Products LLC's request, allows for quicker integration of scientifically sound ingredients.

A New Era for Sunscreen Innovation in the US

The sunscreen treatment landscape over the past five years has fundamentally shifted from traditional trial-based therapeutic development toward consensus-driven, evidence-based formulation innovation and clinical application optimization. This evolution has been characterized by comprehensive expert consensus initiatives, most notably the 2025 Indian Sunscreen Forum consensus statement developed by 14 dermatologists using modified Delphi methodology, and the 2026 Egyptian National Consensus study employing RAND/UCLA appropriateness methods across 601 dermatologists. These collaborative efforts established evidence-based recommendations for formulation selection (physical, chemical, and hybrid), application protocols, and indication-specific guidance spanning melasma, photodermatoses, acne, and post-procedural care, while addressing special population considerations for pediatric, pregnant, and sensitive skin populations.

Clinical trial data has revealed significant advances in active ingredient development and delivery mechanisms that enhance both efficacy and safety profiles. Novel formulations incorporating natural polyphenolic antioxidants from green tea and pomegranate peel extracts achieved SPF values of 16.32 with improved photostability, while advanced nanotechnology platforms such as OMC-loaded hollow mesoporous silica nanoparticles with polydopamine coating demonstrated remarkable performance improvements, achieving SPF up to 54 and UVAPF up to 26.8. Additionally, innovative biocompatible formulations utilizing L-tryptophan combined with sunflower lecithin provided ecofriendly UVB photoprotection while engaging aryl hydrocarbon receptor pathways, representing a paradigm shift toward multimechanistic photoprotection beyond traditional UV filtering.

The regulatory and clinical application landscape has simultaneously evolved toward comprehensive, region-specific frameworks that address global variations in environmental conditions and population needs. The 2026 global regulatory review highlighted the necessity for latitude-, climate-, and lifestyle-specific SPF requirements across major regulatory authorities including FDA, EU COLIPA, and Health Canada, while maintaining harmonized international testing standards. Clinical validation studies demonstrated that sunscreen efficacy remains uncompromised when combined with topical therapeutics including corticosteroids, antibiotics, and antifungals in photodermatosis management, with enhanced protective effects observed in specific combination protocols, thereby expanding therapeutic applications while addressing safety concerns regarding systemic absorption and environmental impact.

Bemotrizinol: A Safe and Effective New UV Filter

Published safety and tolerability data for Bemotrizinol demonstrates a favorable profile across preclinical and formulation studies. In a 2025 study utilizing Saccharomyces cerevisiae mutant strains sensitive to UVA, UVB, and Solar Simulated Light, Bemotrizinol was evaluated for both photoprotective efficacy and mutagenic potential using new approach methodology (NAMs). This preclinical assessment compared Bemotrizinol against other UV filters including diethylamino hydroxybenzoyl hexyl benzoate (DHHB) and octyl methoxycinnamate (OMC) to establish safety profiles for photoprotection applications.

Formulation studies have successfully demonstrated Bemotrizinol's compatibility with advanced delivery systems without safety concerns. A 2026 study showed successful encapsulation of bis-ethylhexyloxyphenol methoxyphenyl triazine (Bemotrizinol) in nanostructured lipid carriers alongside other UV filters, with encapsulation efficiency exceeding 70% and analytical validation meeting ICH guidelines. Additionally, a 2016 study incorporated Bemotrizinol (Tinosorb S) as a sunscreen additive in ofloxacin ointments, where no relevant differences in genotoxicity or toxicity were observed compared to control formulations.

Market surveillance data supports Bemotrizinol's established safety profile, as evidenced by its identification in a 2021 Thai market survey as the most commonly used UV filter in pediatric sunscreen formulations. This widespread use in products intended for children, a particularly sensitive population, underscores the regulatory acceptance and safety confidence in Bemotrizinol across different geographic markets and demographic applications.

Addressing Unmet Needs in Sun Protection

Current sunscreen approaches face significant challenges that complicate optimal patient care and outcomes. Healthcare providers must navigate complex decisions involving product selection, safety considerations, and patient compliance factors. These limitations highlight the need for more personalized and evidence-based approaches to sun protection.

• Product selection complexity: Clinicians face practical dilemmas in selecting sunscreens that balance efficacy, cosmetic acceptability, affordability, and patient adherence due to wide variability in skin types, dermatologic conditions, climates, and formulation preferences

• Safety concerns with emerging technologies: Systemic absorption from nanotechnology-based formulations requires further investigation, and natural extracts can produce unexpected effects, such as Vaccinium myrtillus L. extract reducing SPF despite being photostable and safe

• Environmental and manufacturing challenges: Environmental impact of sunscreens presents ongoing concerns, while technical issues like particle aggregation in microcrystalline cellulose@nano-TiO₂ core-shell composites create manufacturing difficulties and increase risks of adverse effects

• Variable protective efficacy: Active sunscreen ingredients demonstrate inconsistent protective effects across the UVR and visible light spectrum, and limited attention is directed to UV exposure through window glass or sunglasses

• Need for personalized approaches: Appropriate sunscreen formulation selection depends on multiple individual factors, requiring healthcare providers to maintain awareness of evolving formulations to facilitate informed product selection and patient counseling

Bemotrizinol: Reshaping the U.S. Sunscreen Landscape

The recent FDA approval of bemotrizinol marks a significant turning point for the U.S. sunscreen market, introducing the first new active ingredient in decades. This move is not merely an expansion of options; it represents a critical step towards modernizing photoprotection in the United States, aligning it more closely with international standards. Bemotrizinol, a broad-spectrum filter already safely used in Europe, offers robust protection against both UVA and UVB rays with the added benefit of low skin absorption, making it a valuable asset in the fight against rising skin cancer rates. Its designation as Generally Recognized As Safe and Effective (GRASE) for a wide age range, including children as young as 6 months, addresses a key public health need for safer and more effective sunscreens.

This approval, facilitated by the streamlined OTC Monograph Order Request (OMOR) process, signals a promising pathway for other advanced UV filters to enter the U.S. market. For pharmaceutical and cosmetic companies, this opens up substantial opportunities for innovation:

• Enhanced Product Development: Manufacturers can now formulate sunscreens with superior efficacy, potentially combining bemotrizinol with antioxidants like ferulic acid to create multifunctional products that not only block UV radiation but also offer anti-inflammatory benefits and increased SPF/UVA-PF.

• Advanced Delivery Systems: The integration of bemotrizinol into novel delivery systems, such as nanostructured lipid carriers, could further optimize its performance and stability, pushing the boundaries of photoprotection technology.

However, this evolution also brings considerations. While bemotrizinol itself has a favorable safety profile, the broader class of chemical UV filters has raised concerns regarding potential allergen sensitization, particularly in products marketed for sensitive skin or children. Therefore, rigorous formulation and clear labeling will remain paramount. Furthermore, the complexity of integrating new filters into advanced formulations necessitates robust analytical validation to ensure product quality and efficacy. Finally, effective consumer education will be vital to ensure proper application, understanding of benefits, and awareness of removal best practices, maximizing the public health impact of these new advancements. This approval is a clear signal that the U.S. market is ready for a new generation of sunscreens.